Teva names new CEO

Share this article:

The rumors are true: Erez Vigodman is Teva Pharmaceutical's new president and CEO. The Jerusalem, Israel, company said in the Thursday announcement that he will officially take on the roles February 11.

The appointment will end a public relations rough patch which included the October announcement that Teva was laying off 10% of its staff to limit the impact of generic Copaxone, which was soon followed by a public “was he fired or was he pushed?” feud that saw then-CEO Jeremy Levin leave the company. Eyal Desheh stepped in as acting president and CEO. He will now slide back into his role as group EVP and CFO.

Vigodman was already on Teva's board and currently heads up the generic agrochemical company Makhteshim Agan Industries. Teva said in a statement that Vigodman will stay with MAI until February 6.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

IRS struggles with device tax

A Treasury report says the IRS is having trouble identifying who owes it money.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.